Novo Nordisk inks pact on 'killer' cells

Novo Nordisk upped its stake in Innate Pharma to about 20 percent as it inked a three-year collaboration to develop new therapies to boost the work of natural killer cells that protect the body from cancer and infections. Innate also stands to gain 25 million euros in up front payments, preclinical milestones and research support. Novo Nordisk--which saw its shares boosted by news of the pact--is looking at new therapies in three key areas: cancer, autoimmune disorders and infection.

- here's the AFX report

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.